Pasithea Therapeutics Corp Stock Buy Hold or Sell Recommendation
| KTTAW Stock | USD 0.02 0 11.11% |
Assuming the 90 days horizon and your complete indifference towards market risk, our recommendation regarding Pasithea Therapeutics Corp is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Pasithea Therapeutics Corp given historical horizon and risk tolerance towards Pasithea Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Pasithea Therapeutics Corp, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Pasithea Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Pasithea and provide practical buy, sell, or hold advice based on investors' constraints. Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Pasithea |
Execute Pasithea Therapeutics Buy or Sell Advice
The Pasithea recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Pasithea Therapeutics Corp. Macroaxis does not own or have any residual interests in Pasithea Therapeutics Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Pasithea Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Pasithea Therapeutics Trading Alerts and Improvement Suggestions
| Pasithea Therapeutics is way too risky over 90 days horizon | |
| Pasithea Therapeutics has some characteristics of a very speculative penny stock | |
| Pasithea Therapeutics appears to be risky and price may revert if volatility continues | |
| Pasithea Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 486.56 K. Net Loss for the year was (15.51 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pasithea Therapeutics Corp has accumulated about 568.98 K in cash with (13.43 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Pasithea Therapeutics announces SRC recommended proceeding to cohort 4 - TipRanks |
Pasithea Therapeutics Returns Distribution Density
The distribution of Pasithea Therapeutics' historical returns is an attempt to chart the uncertainty of Pasithea Therapeutics' future price movements. The chart of the probability distribution of Pasithea Therapeutics daily returns describes the distribution of returns around its average expected value. We use Pasithea Therapeutics Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Pasithea Therapeutics returns is essential to provide solid investment advice for Pasithea Therapeutics.
| Mean Return | 5.81 | Value At Risk | -31.89 | Potential Upside | 61.29 | Standard Deviation | 29.02 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Pasithea Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Pasithea Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Pasithea Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Pasithea Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Pasithea stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 5.60 | |
β | Beta against Dow Jones | 2.04 | |
σ | Overall volatility | 177.11 | |
Ir | Information ratio | 0.20 |
Pasithea Therapeutics Volatility Alert
Pasithea Therapeutics Corp is showing large volatility of returns over the selected time horizon. Pasithea Therapeutics Corp is a penny stock. Although Pasithea Therapeutics may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Pasithea Therapeutics Corp. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Pasithea instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Pasithea Therapeutics Fundamentals Vs Peers
Comparing Pasithea Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pasithea Therapeutics' direct or indirect competition across all of the common fundamentals between Pasithea Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pasithea Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Pasithea Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Pasithea Therapeutics to competition |
| Fundamentals | Pasithea Therapeutics | Peer Average |
| Return On Equity | -0.63 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Number Of Shares Shorted | 64 | 4.71 M |
| Revenue | 486.56 K | 9.43 B |
| EBITDA | (15.33 M) | 3.9 B |
| Net Income | (15.51 M) | 570.98 M |
| Cash And Equivalents | 568.98 K | 2.7 B |
| Cash Per Share | 0.07 X | 5.01 X |
| Total Debt | 81.68 K | 5.32 B |
| Current Ratio | 37.55 X | 2.16 X |
| Book Value Per Share | 22.46 X | 1.93 K |
| Cash Flow From Operations | (13.43 K) | 971.22 M |
| Number Of Employees | 8 | 18.84 K |
| Beta | 0.82 | -0.15 |
| Total Asset | 26.12 M | 29.47 B |
| Retained Earnings | (35.32 M) | 9.33 B |
| Working Capital | 14.06 M | 1.48 B |
| Net Asset | 26.12 M |
Note: Disposition of tradable shares by Pd Joint Holdings, Llc Series 2016-a of Pasithea Therapeutics subject to Rule 16b-3 [view details]
Pasithea Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Pasithea . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Pasithea Therapeutics Buy or Sell Advice
When is the right time to buy or sell Pasithea Therapeutics Corp? Buying financial instruments such as Pasithea Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Pasithea Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.